top of page

Radiopharmaceuticals at Scale: Can Oncology Build the Infrastructure This Modality Requires?

sharonshieldsconsu
Oct 21
4 min read

Radiopharmaceuticals have shifted from technical curiosity to strategic priority. Targeted radiotherapies are now central to multiple big‑pharma oncology strategies, deal flow is intense, and pipelines are filling with agents that marry precision targeting to therapeutic isotopes.


The scientific promise is real. The harder question is whether manufacturing, supply chains and operating models can keep up.


This is not just a new drug class; it’s an industrial challenge.



Question – Why are radiopharmaceuticals suddenly so prominent?


Because they sit at the intersection of precision targeting and familiar radiation biology – and early products have shown they can work and sell.


  • Clinicians already understand radiation.

  • New agents bring molecular targeting (e.g. PSMA, SSTR) and theranostic pairs.

  • Early launches in prostate cancer and neuroendocrine tumours have delivered meaningful efficacy in late‑line patients.


That combination has triggered:


  • Major acquisitions and long‑term partnering,

  • A race to lock in isotope supply, and

  • Competition for people who understand both oncology and nuclear operations.


The science is advancing quickly. The infrastructure is not.



Question – What makes radiopharmaceutical manufacturing fundamentally different?


You aren’t just adding a new raw material to an existing biologics plant. You’re running a time‑pressured, dual‑regulated nuclear supply chain.


Three characteristics matter:

  1. Half‑life and time pressure

    • Isotopes decay rapidly – often over hours or days.

    • Production is essentially make‑to‑order, where delays mean lost product and missed patients.

  2. Dual regulatory oversight

    • Full GMP expectations from medicines regulators.

    • Nuclear licensing, radiation protection and transport approvals from separate authorities.

    • Facility design, quality systems and documentation must satisfy two sets of rules that rarely speak the same language.

  3. Specialised facilities and skills

    • Hot cells, shielded lines, dedicated QC, waste handling.

    • Talent from radiochemistry, nuclear medicine, GMP manufacturing and hospital radiopharmacy – disciplines that historically sat in different worlds.


Operationally, radiopharmaceuticals behave as much like a time‑critical industrial service as a classic “make, warehouse, distribute” drug product.



Question – Where are the bottlenecks as the field scales?


The pressure points are already visible:


  • Isotope production and security of supply

    Limited reactor / cyclotron capacity, competing demand and geopolitical risk make isotope contracts a strategic asset, not a commodity purchase.

  • GMP radiopharma capacity

    Only a small number of sites can run commercial‑scale radiopharmaceutical lines under both GMP and nuclear regulation. Retrofitting is slow; greenfield is expensive and talent‑intensive.

  • Cold chain and last‑mile logistics

    Product must move within tight time windows to centres with variable readiness. Aligning manufacturing, transport, radiopharmacy and clinic schedules is an orchestration problem, not simple distribution.

  • Leadership and operating model

    Most oncology organisations were built around small molecules and biologics (and, increasingly, cell therapy). Radiopharmaceuticals require leaders comfortable with industrial engineering, nuclear compliance and oncology markets in the same conversation.


These constraints will shape not only who wins, but how fast the modality can grow at all.



Question – How should companies think about “build vs buy vs partner”?


Manufacturing and supply choices are now strategic, not back‑office.


  • Build (vertical integration)

    • Control over capacity, quality and scheduling.

    • Ability to differentiate on reliability and service to treatment centres.

    • High capital, long lead times, and heavy demands on manufacturing and engineering leadership.

  • Buy (acquisitions)

    • Faster access to licensed sites, isotope contracts and experienced teams.

    • Integration risk: cultural clash between nuclear ops and classic pharma; risk of overpaying for constrained assets.

  • Partner (alliances / CDMOs)

    • De‑risks capex; leverages existing nuclear infrastructure.

    • Less control during disruptions; competition for slots with other sponsors.


In practice, the credible strategies will be hybrid – own critical nodes in the network, partner where scale or geography makes that more rational.


The common denominator: manufacturing and supply must be designed into the modality from day one, not retrofitted two years before launch.



Question – What does this mean for leadership and talent?


Radiopharmaceuticals are forcing a rethink of how organisations connect R&D, operations and the clinic.


  • Cross‑disciplinary leadership

    Teams need leaders who can integrate nuclear operations, pharma manufacturing, QA/Reg, supply chain and oncology commercial strategy.

  • Early operational input

    “Can we make and deliver this reliably?” needs to be a gating question at early portfolio decision points, not an afterthought behind a promising Phase 2.

  • Closer hospital–industry integration

    Success depends on how well companies can synchronise production slots, logistics and treatment capacity across a distributed network of centres.


For boards and executives, the strategic question is shifting from “Should we have a radiopharmaceuticals play?” to “Do we have the operating model and leadership to run this modality safely and predictably at scale?”



Where I fit


I work with life sciences organisations globally on exactly these issues: building and stress‑testing manufacturing and supply strategies for complex modalities, including radiopharmaceuticals, cell and gene therapies and biologics.


If you’re wrestling with how to:

  • design a radiopharma network,

  • find and assess leaders who can run this modality at scale





References

  1. Challenges and opportunities in radioligand therapy. Theranostics. 2026;16(4):1234–1256. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12688045/

  2. Radioligand therapy in cancer management: a global perspective. Eur J Nucl Med Mol Imaging. 2025;52(7):2103–2119. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12607575/

  3. Radiopharmaceuticals and theranostics: the high road ahead. Oncology Research Reviews. 2026;5(2):45–59. Available at: http://srcpublishers.com/oncology-research-reviews-report/article/download/2265/8131/28567

  4. Recent advances in radiopharmaceuticals for cancer diagnosis and therapy. Cancers (Basel). 2026;18(3):654. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC13040343/

  5. Radioligand therapy: seizing the opportunity. ClearView Healthcare Partners. 2024. Available at: https://clearviewhcp.com/wp-content/uploads/2024/03/Radioligand-Therapy-Seizing-The-Opportunity.pdf

  6. Leveraging opportunities in radiopharmaceuticals. KPMG. 2024. Available at: https://assets.kpmg.com/content/dam/kpmgsites/uk/pdf/2024/12/leveraging-opportunities-in-radiopharm.pdf

  7. Radiopharmaceuticals: operational implications in strategic oncology. Worldwide Clinical Trials. 2025. Available at: https://www.worldwide.com/wp-content/uploads/2025/09/Oncology-WhitePaper-Rhadiopharmaceuticals-Operational-Implications.pdf

  8. Draft guideline on radiopharmaceuticals. European Medicines Agency. 2025. Available at: https://www.ema.europa.eu/system/files/documents/scientific-guideline/gl-radiopharmaceuticals-consultation-en.pdf

Comments

Rated 0 out of 5 stars.
No ratings yet

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page